APAC SJS TEN Treatment Market - Industry Trends and Forecast to 2030 | Pharmaceutical_LifeSciense Market Research Report

Abstract

Summary

Asia-Pacific SJS/TEN treatment market is expected to reach USD 5,257.31 million by 2030 from USD 2,741.31 million in 2022 growing at the CAGR of 8.6% during the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030. Market Segmentation: Asia-Pacific SJS/TEN Treatment Market, By Treatment (Medications, Support Care, Hospitalization, Isolation, Ointments, and Others), Diagnosis (Physical Exam, Skin Biopsy, Medical History, Blood Test, Cultures, and Others), Cause (Specific Treatment, Infection, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Drug Type (Branded and Generic), Therapy Area (Combination Therapy and Monotherapy), Patient Type (Geriatric, Adult, and Pediatric), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center, Homecare Setting, and Others), Distribution Channel (Retail Pharmacies, Direct Tender, and Others), Country (China, Japan, India, New Zealand, Australia, South Korea, Indonesia, Philippines, Thailand, Malaysia, Singapore, Vietnam, Taiwan, Rest of Asia-Pacific) - Industry Trends & Forecast to 2030 Overview of Asia-Pacific SJS/TEN Treatment Market Dynamics: Driver • Rising number of diseases as these TEN/SJS are severe mucocutaneous reactions triggered mainly by exposure to medications Restrain • High cost associated with SJS/TEN treatment Opportunity • Developing effective and safe treatments for SJS/TEN treatment Market Players: Some of the key market players operating in the Asia-Pacific SJS/TEN treatment market are listed below: • 3M • Cardinal Health • BD • Smith + Nephew • Novartis AG • Amneal Pharmaceuticals LLC. • Pfizer Inc. • Colgate-Palmolive Company • Merck & Co., Inc. • Mölnlycke Health Care AB. • Xttrium Laboratories • ICPA Health Products Ltd • Purdue Pharma L.P. • eugia (Subsidiary of Aurobindo Pharma) • AdvaCare Pharma

1 INTRODUCTION 84
- 1.1 OBJECTIVES OF THE STUDY 84
- 1.2 MARKET DEFINITION 84
- 1.3 OVERVIEW OF THE ASIA-PACIFIC SJS/TEN TREATMENT MARKET 84
- 1.4 LIMITATIONS 87
- 1.5 MARKETS COVERED 87
2 MARKET SEGMENTATION 92
- 2.1 MARKETS COVERED 92
- 2.2 GEOGRAPHICAL SCOPE 93
- 2.3 YEARS CONSIDERED FOR THE STUDY 94
- 2.4 CURRENCY AND PRICING 94
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 95
- 2.6 MULTIVARIATE MODELLING 98
- 2.7 TREATMENT LIFELINE CURVE 98
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 99
- 2.9 DBMR MARKET POSITION GRID 100
- 2.10 MARKET APPLICATION COVERAGE GRID 101
- 2.11 VENDOR SHARE ANALYSIS 102
- 2.12 SECONDARY SOURCES 103
- 2.13 ASSUMPTIONS 103
3 EXECUTIVE SUMMARY 104
4 PREMIUM INSIGHTS 107
- 4.1 KEY TRENDS 108
- 4.2 COST OF TREATMENT 109
- 4.3 KEY PLAYERS STRATEGIES 110
- 4.4 LONG TERM GROWTH APPROACH 111
5 EPIDEMIOLOGY 112
6 INDUSTRY INSIGHTS 116
- 6.1 PATENT ANALYSIS 116
- 6.2 DEMOGRAPHIC TRENDS 118
- 6.3 PATIENT FLOW DIAGRAM 119
- 6.4 KEY PRICING STRATEGIES 120
- 6.5 KEY PATIENT ENROLLMENT STRATEGIES 120
7 MARKET OVERVIEW 123
- 7.1 DRIVERS 125
  - 7.1.1 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN 125
  - 7.1.2 ADVANCES IN DRUG DEVELOPMENT FOR SJS/TEN TREATMENT 126
  - 7.1.3 INCREASING AWARENESS ABOUT THE RARE DISEASE SJS/TEN 126
  - 7.1.4 GOVERNMENT INITIATIVES FOR SJS/TEN TREATMENT 127
- 7.2 RESTRAINTS 129
  - 7.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT OF SJS/TEN 129
  - 7.2.2 LIMITED AVAILABILITY OF SPECIALIZED CARE FOR SJS/TEN TREATMENT 129
- 7.3 OPPORTUNITIES 130
  - 7.3.1 DEVELOPING EFFECTIVE AND SAFE TREATMENT FOR SJS/TEN 130
  - 7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR SJS/TEN TREATMENT 131
- 7.4 CHALLENGES 131
  - 7.4.1 STRINGENT GOVERNMENT REGULATIONS FOR APPROVAL OF TREATMENT FOR SJS/TEN 131
  - 7.4.2 LONG TERM COMPLICATIONS AND ADVERSE EFFECTS OF MEDICATIONS USED IN THE SJS/TEN TREATMENT 132
8 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY TREATMENT 133
- 8.1 OVERVIEW 134
- 8.2 MEDICATIONS 137
  - 8.2.1 ANTIHISTAMINES 138
    - 8.2.1.1 HYDROXYZINE 138
    - 8.2.1.2 FEXOFENADINE 138
  - 8.2.2 CORTICOSTEROID 139
    - 8.2.2.1 DEXAMETHASONE 139
    - 8.2.2.2 PREDNISOLONE 139
    - 8.2.2.3 METHYLPREDNISOLONE 139
    - 8.2.2.4 HYDROCORTISONE 139
    - 8.2.2.5 OTHERS 139
  - 8.2.3 ANTIBIOTICS 139
    - 8.2.3.1 NAFCILLIN 140
    - 8.2.3.2 GENTAMICIN 140
    - 8.2.3.3 OTHERS 140
  - 8.2.4 ANALGESICS 140
    - 8.2.4.1 MORPHINE 140
    - 8.2.4.2 FENTANYL CITRATE 141
    - 8.2.4.3 OTHERS 141
  - 8.2.5 ANTICOAGULANTS 141
  - 8.2.6 ANTISEPTICS 141
    - 8.2.6.1 CHLORHEXIDINE GLUCONATE 141
      - 8.2.6.1.1 PERIOGARD 142
      - 8.2.6.1.2 PERIDEX 142
      - 8.2.6.1.3 AVAGARD 142
      - 8.2.6.1.4 HIBICLENS 142
      - 8.2.6.1.5 OTHERS 142
    - 8.2.6.2 OCTENISEPT 142
    - 8.2.6.3 POLYHEXANIDE SOLUTIONS 142
    - 8.2.6.4 OTHERS 143
  - 8.2.7 INTRAVENOUS IMMUNOGLOBULIN 143
  - 8.2.8 CYCLOSPORINE 143
    - 8.2.8.1 NEORAL 143
    - 8.2.8.2 SANDIMMUNE 143
    - 8.2.8.3 OTHERS 143
  - 8.2.9 TUMOR NECROSIS FACTOR-ALPHA (TNF-Α)-BLOCKING AGENT (ETANERCEPT) 143
  - 8.2.10 OTHER TREATMENT 144
    - 8.2.10.1 CYCLOPHOSPHAMIDE 144
    - 8.2.10.2 N-ACETYLCYSTEINE 144
    - 8.2.10.3 MONOCLONAL ANTIBODIES 144
    - 8.2.10.4 THALIDOMIDE 144
- 8.3 SUPPORT CARE 144
  - 8.3.1 INTRAVENOUS (IV) FLUID AND ELECTROLYTES 145
  - 8.3.2 PAIN MANAGEMENT 146
    - 8.3.2.1 LIDOCAINE 146
    - 8.3.2.2 OTHERS 146
  - 8.3.3 NUTRITION SUPPORT 146
  - 8.3.4 ORAL CARE 146
  - 8.3.5 PLASMAPHERESIS 146
  - 8.3.6 BANDAGES 146
    - 8.3.6.1 BIOLOGICAL DRESSING 147
      - 8.3.6.1.1 ALLOGRAFT 147
      - 8.3.6.1.2 XENOGRAFT 147
      - 8.3.6.1.3 HOMOGRAFT 147
      - 8.3.6.1.4 OTHERS 147
    - 8.3.6.2 BIOSYNTHETIC DRESSING 148
    - 8.3.6.3 SILVER IMPREGNATED DRESSING 148
- 8.4 HOSPITALIZATION 148
- 8.5 ISOLATION 149
- 8.6 OINTMENTS 149
  - 8.6.1 BENZOCAINE 150
  - 8.6.2 AMERICAINE 150
  - 8.6.3 ANBESOL 150
  - 8.6.4 CHIGGEREX PLUS 150
  - 8.6.5 OTHERS 151
- 8.7 OTHERS 151
9 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY DIAGNOSIS 152
- 9.1 OVERVIEW 153
- 9.2 PHYSICAL EXAM 156
- 9.3 SKIN BIOPSY 156
- 9.4 MEDICAL HISTORY 157
- 9.5 BLOOD TEST 158
  - 9.5.1 COMPLETE BLOOD COUNT 159
  - 9.5.2 ERYTHROCYTE SEDIMENTATION RATE 159
  - 9.5.3 COAGULATION STUDIES 159
  - 9.5.4 UREA AND ELECTROLYTES 160
  - 9.5.5 LIVER FUNCTION TEST 160
- 9.6 CULTURES 160
- 9.7 OTHERS 161
10 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY CAUSE 162
- 10.1 OVERVIEW 163
- 10.2 SPECIFIC TREATMENT 166
- 10.3 INFECTION 166
- 10.4 OTHERS 167
11 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 168
- 11.1 OVERVIEW 169
- 11.2 ORAL 172
- 11.3 PARENTERAL 172
  - 11.3.1 INTRAVENOUS 173
  - 11.3.2 SUBCUTANEOUS 173
  - 11.3.3 OTHERS 173
- 11.4 TOPICAL 173
  - 11.4.1 OINTMENTS 174
  - 11.4.2 SOLUTION 174
  - 11.4.3 CREAMS 175
  - 11.4.4 OTHERS 175
- 11.5 OTHERS 175
12 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY DRUG TYPE 176
- 12.1 OVERVIEW 177
- 12.2 BRANDED 180
  - 12.2.1 NEORAL 181
  - 12.2.2 SANDIMMUNE 181
  - 12.2.3 VISTARIL 181
  - 12.2.4 DURAMORPH 181
  - 12.2.5 FENTORA 181
  - 12.2.6 ENBREL 181
  - 12.2.7 OTHERS 181
- 12.3 GENERIC 181
13 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY THERAPY TYPE 183
- 13.1 OVERVIEW 184
- 13.2 COMBINATION THERAPY 187
- 13.3 MONOTHERAPY 187
14 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY PATIENT TYPE 189
- 14.1 OVERVIEW 190
- 14.2 GERIATRIC 193
  - 14.2.1 FEMALE 194
  - 14.2.2 MALE 194
- 14.3 ADULT 194
  - 14.3.1 FEMALE 195
  - 14.3.2 MALE 195
- 14.4 PEDIATRIC 195
15 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY END USER 197
- 15.1 OVERVIEW 198
- 15.2 HOSPITALS 201
- 15.3 SPECIALTY CLINICS 201
- 15.4 AMBULATORY SURGICAL CENTER 202
- 15.5 HOMECARE SETTING 203
- 15.6 OTHERS 203
16 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL 205
- 16.1 OVERVIEW 206
- 16.2 RETAIL PHARMACIES 209
  - 16.2.1 HOSPITAL ASSOCIATED PHARMACIES 210
  - 16.2.2 DRUG STORE 210
  - 16.2.3 ONLINE PHARMACIES 210
- 16.3 DIRECT TENDERS 210
- 16.4 OTHERS 211
17 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY REGION 212
- 17.1 ASIA-PACIFIC 213
  - 17.1.1 CHINA 230
  - 17.1.2 JAPAN 241
  - 17.1.3 INDIA 252
  - 17.1.4 SOUTH KOREA 263
  - 17.1.5 AUSTRALIA 274
  - 17.1.6 SINGAPORE 285
  - 17.1.7 THAILAND 295
  - 17.1.8 INDONESIA 306
  - 17.1.9 PHILIPPINES 316
  - 17.1.10 MALAYSIA 326
  - 17.1.11 NEW ZEALAND 336
  - 17.1.12 VIETNAM 347
  - 17.1.13 TAIWAN 358
  - 17.1.14 REST OF ASIA-PACIFIC 369
18 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, COMPANY LANDSCAPE 370
- 18.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 370
19 SWOT ANALYSIS 371
20 COMPANY PROFILE 372
- 20.1 PFIZER INC 372
  - 20.1.1 COMPANY SNAPSHOT 372
  - 20.1.2 REVENUE ANALYSIS 372
  - 20.1.3 COMPANY SHARE ANALYSIS 373
  - 20.1.4 PRODUCT PORTFOLIO 373
  - 20.1.5 RECENT DEVELOPMENT 373
- 20.2 NOVARTIS AG 374
  - 20.2.1 COMPANY SNAPSHOT 374
  - 20.2.2 REVENUE ANALYSIS 374
  - 20.2.3 COMPANY SHARE ANALYSIS 375
  - 20.2.4 PRODUCT PORTFOLIO 375
  - 20.2.5 RECENT DEVELOPMENT 375
- 20.3 MERCK & CO., INC 376
  - 20.3.1 COMPANY SNAPSHOT 376
  - 20.3.2 REVENUE ANALYSIS 376
  - 20.3.3 COMPANY SHARE ANALYSIS 377
  - 20.3.4 PRODUCT PORTFOLIO 377
  - 20.3.5 RECENT DEVELOPMENT 377
- 20.4 AMNEAL PHARMACEUTICAL LLC 378
  - 20.4.1 COMPANY SNAPSHOT 378
  - 20.4.2 REVENUE ANALYSIS 378
  - 20.4.3 COMPANY SHARE ANALYSIS 379
  - 20.4.4 PRODUCT PORTFOLIO 379
  - 20.4.5 RECENT DEVELOPMENT 379
- 20.5 AMGEN INC 380
  - 20.5.1 COMPANY SNAPSHOT 380
  - 20.5.2 REVENUE ANALYSIS 380
  - 20.5.3 PRODUCT PORTFOLIO 381
  - 20.5.4 RECENT DEVELOPMENT 381
- 20.6 ADVACARE PHARMA 382
  - 20.6.1 COMPANY SNAPSHOT 382
  - 20.6.2 PRODUCT PORTFOLIO 382
  - 20.6.3 RECENT DEVELOPMENT 382
- 20.7 BD 383
  - 20.7.1 COMPANY SNAPSHOT 383
  - 20.7.2 REVENUE ANALYSIS 383
  - 20.7.3 PRODUCT PORTFOLIO 384
  - 20.7.4 RECENT DEVELOPMENT 384
- 20.8 CARDINAL HEALTH 385
  - 20.8.1 COMPANY SNAPSHOT 385
  - 20.8.2 REVENUE ANALYSIS 385
  - 20.8.3 PRODUCT PORTFOLIO 386
  - 20.8.4 RECENT DEVELOPMENT 386
- 20.9 COLGATE-PALMOLIVE COMPANY 387
  - 20.9.1 COMPANY SNAPSHOT 387
  - 20.9.2 REVENUE ANALYSIS 387
  - 20.9.3 PRODUCT PORTFOLIO 388
  - 20.9.4 RECENT DEVELOPMENT 388
- 20.10 EUGIA (SUBSIDIARY OF AUROBINDO PHARMA) 389
  - 20.10.1 COMPANY SNAPSHOT 389
  - 20.10.2 REVENUE ANALYSIS 389
  - 20.10.3 PRODUCT PORTFOLIO 390
  - 20.10.4 RECENT DEVELOPMENT 390
- 20.11 ICPA HEALTH PRODUCTS LTD 391
  - 20.11.1 COMPANY SNAPSHOT 391
  - 20.11.2 PRODUCT PORTFOLIO 391
  - 20.11.3 RECENT DEVELOPMENT 391
- 20.12 3M 392
  - 20.12.1 COMPANY SNAPSHOT 392
  - 20.12.2 REVENUE ANALYSIS 392
  - 20.12.3 PRODUCT PORTFOLIO 393
  - 20.12.4 RECENT DEVELOPMENT 393
- 20.13 MOLNLYCKE HEALTH CARE AB 394
  - 20.13.1 COMPANY SNAPSHOT 394
  - 20.13.2 PRODUCT PORTFOLIO 394
  - 20.13.3 RECENT DEVELOPMENT 394
- 20.14 PURDUE PHARMA L.P 395
  - 20.14.1 COMPANY SNAPSHOT 395
  - 20.14.2 PRODUCT PORTFOLIO 395
  - 20.14.3 RECENT DEVELOPMENT 395
- 20.15 SCHULKE & MAYR GMBH 396
  - 20.15.1 COMPANY SNAPSHOT 396
  - 20.15.2 PRODUCT PORTFOLIO 396
  - 20.15.3 RECENT DEVELOPMENT 396
- 20.16 SMITH + NEPHEW 397
  - 20.16.1 COMPANY SNAPSHOT 397
  - 20.16.2 REVENUE ANALYSIS 397
  - 20.16.3 PRODUCT PORTFOLIO 398
  - 20.16.4 RECENT DEVELOPMENT 398
- 20.17 XTTRIUM LABORATORIES 399
  - 20.17.1 COMPANY SNAPSHOT 399
  - 20.17.2 PRODUCT PORTFOLIO 399
  - 20.17.3 RECENT DEVELOPMENT 399
21 QUESTIONNAIRE 400
22 RELATED REPORTS 404

APAC SJS TEN Treatment Market - Industry Trends and Forecast to 2030 ‐ Pharmaceutical_LifeSciense Market

APAC SJS TEN Treatment Market - Industry Trends and Forecast to 2030 ‐ Pharmaceutical_LifeSciense Market

Abstract

Summary

Table of Contents

1 INTRODUCTION 84

1.1 OBJECTIVES OF THE STUDY 84

1.2 MARKET DEFINITION 84

1.3 OVERVIEW OF THE ASIA-PACIFIC SJS/TEN TREATMENT MARKET 84

1.4 LIMITATIONS 87

1.5 MARKETS COVERED 87

2 MARKET SEGMENTATION 92

2.1 MARKETS COVERED 92

2.2 GEOGRAPHICAL SCOPE 93

2.3 YEARS CONSIDERED FOR THE STUDY 94

2.4 CURRENCY AND PRICING 94

2.5 DBMR TRIPOD DATA VALIDATION MODEL 95

2.6 MULTIVARIATE MODELLING 98

2.7 TREATMENT LIFELINE CURVE 98

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 99

2.9 DBMR MARKET POSITION GRID 100

2.10 MARKET APPLICATION COVERAGE GRID 101

2.11 VENDOR SHARE ANALYSIS 102

2.12 SECONDARY SOURCES 103

2.13 ASSUMPTIONS 103

3 EXECUTIVE SUMMARY 104

4 PREMIUM INSIGHTS 107

4.1 KEY TRENDS 108

4.2 COST OF TREATMENT 109

4.3 KEY PLAYERS STRATEGIES 110

4.4 LONG TERM GROWTH APPROACH 111

5 EPIDEMIOLOGY 112

6 INDUSTRY INSIGHTS 116

6.1 PATENT ANALYSIS 116

6.2 DEMOGRAPHIC TRENDS 118

6.3 PATIENT FLOW DIAGRAM 119

6.4 KEY PRICING STRATEGIES 120

6.5 KEY PATIENT ENROLLMENT STRATEGIES 120

7 MARKET OVERVIEW 123

7.1 DRIVERS 125

7.1.1 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN 125

7.1.2 ADVANCES IN DRUG DEVELOPMENT FOR SJS/TEN TREATMENT 126

7.1.3 INCREASING AWARENESS ABOUT THE RARE DISEASE SJS/TEN 126

7.1.4 GOVERNMENT INITIATIVES FOR SJS/TEN TREATMENT 127

7.2 RESTRAINTS 129

7.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT OF SJS/TEN 129

7.2.2 LIMITED AVAILABILITY OF SPECIALIZED CARE FOR SJS/TEN TREATMENT 129

7.3 OPPORTUNITIES 130

7.3.1 DEVELOPING EFFECTIVE AND SAFE TREATMENT FOR SJS/TEN 130

7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR SJS/TEN TREATMENT 131

7.4 CHALLENGES 131

7.4.1 STRINGENT GOVERNMENT REGULATIONS FOR APPROVAL OF TREATMENT FOR SJS/TEN 131

7.4.2 LONG TERM COMPLICATIONS AND ADVERSE EFFECTS OF MEDICATIONS USED IN THE SJS/TEN TREATMENT 132

8 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY TREATMENT 133

8.1 OVERVIEW 134

8.2 MEDICATIONS 137

8.2.1 ANTIHISTAMINES 138

8.2.2 CORTICOSTEROID 139

8.2.3 ANTIBIOTICS 139

8.2.4 ANALGESICS 140

8.2.5 ANTICOAGULANTS 141

8.2.6 ANTISEPTICS 141

8.2.7 INTRAVENOUS IMMUNOGLOBULIN 143

8.2.8 CYCLOSPORINE 143

8.2.9 TUMOR NECROSIS FACTOR-ALPHA (TNF-Α)-BLOCKING AGENT (ETANERCEPT) 143

8.2.10 OTHER TREATMENT 144

8.3 SUPPORT CARE 144

8.3.1 INTRAVENOUS (IV) FLUID AND ELECTROLYTES 145

8.3.2 PAIN MANAGEMENT 146

8.3.3 NUTRITION SUPPORT 146

8.3.4 ORAL CARE 146

8.3.5 PLASMAPHERESIS 146

8.3.6 BANDAGES 146

8.4 HOSPITALIZATION 148

8.5 ISOLATION 149

8.6 OINTMENTS 149

8.6.1 BENZOCAINE 150

8.6.2 AMERICAINE 150

8.6.3 ANBESOL 150

8.6.4 CHIGGEREX PLUS 150